MAP2K7 and melanoma: Melanoma proliferation is attributed to targetable activating BRAF mutations in 50% of cases.[2] In 2014, a combined treatment with dabrafenib, a selective BRAF inhibitor (BRAFi), and trametinib, a selective MEK inhibitor (MEKi) was approved by the Food and Drug Administration (FDA) for the treatment of metastatic melanoma.